Checkmate Pharmaceuticals

Acquired by Regeneron / NASDAQ: CMPI
Immune-activating cancer therapy company acquired by Regeneron in 2022, developed vidutolimod.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Cambridge, MA

Initial Investment

2017
Immune-activating cancer therapy company acquired by Regeneron in 2022, developed vidutolimod.

Checkmate Pharmaceuticals (NASDAQ: CMPI) is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. Checkmate Pharmaceuticals was acquired by Regeneron (NASDAQ: REGH) in 2022.